Pharmaceutical Technology

MARCH 17, 2023

Ghryvelin is used for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare and serious condition, as well as for Childhood Onset Growth Hormone Deficiency (CGHD), if approved. Macimorelin is marketed under the brand name Ghryvelin in the EEA and the UK.

Hormones 263

Hormones Licensing Licensing Medicine 263

BioTech 365

APRIL 26, 2021

United States Generic Drugs Market Report 2020-2026: Focus on CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective & Oncology – ResearchAndMarkets.com United States Generic Drugs Market Report 2020-2026: Focus on CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective & (..)

Generic Drugs 40

Generic Drugs Dermatology Hormones Marketing 40

The Pharma Data

JUNE 28, 2023

FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency NEW YORK & MIAMI–(BUSINESS WIRE)– Pfizer Inc. The approval of NGENLA will be significant for children with growth hormone deficiency in the U.S. NYSE: PFE) and OPKO Health Inc. prescribing in August 2023.

Hormones 40

Hormones FDA Approval Clinical Development Medicine 40

Pharmaceutical Technology

SEPTEMBER 8, 2022

Increasing drug failure rates and essential drug shortages have driven the growth of the compounding pharmacies market, which has a high growth potential, especially in emerging economies. Discover the top pharmaceutical compounding companies in contract marketing. Excipients. Active pharmaceutical ingredients (APIs). Packaging. •

Marketing 130

Marketing Pharmacy Containment Sales 130

Pharmaceutical Technology

MARCH 20, 2023

The race for a first-to-market therapy in non-alcoholic steatohepatitis (NASH) has been a marathon, with many companies facing numerous setbacks and failures. As stated above, Madrigal Pharmaceuticals’s resmetirom appears to be closing Intercept’s lead in the race to market for the first approved therapy in NASH in the US.

Marketing 130

Marketing Trials Hormones Clinical Trials 130

BioTech 365

JULY 16, 2021

Global Non-hormonal Therapies for Women’s Health Markets, 2021-2030: Target Indication, Type of Molecule, Purpose of Therapy, Mechanism of Action, Route of Administration, and Key Geographical Regions – ResearchAndMarkets.com Global Non-hormonal Therapies for Women’s Health Markets, 2021-2030: Target Indication, Type of … Continue (..)

Hormones 40

Hormones Marketing 40

pharmaphorum

MARCH 4, 2024

The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan in breast and lung cancer.

Hormones 105

Hormones Antibody Marketing Drugs 105

The Pharma Data

JUNE 12, 2022

Investigational phase 3 data for Sogroya ® ( somapacitan ) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress 1. Based on the results of the REAL 4 study, there is potential for a once-weekly option for children with growth hormone deficiency.”. cm/year, compared to 11.7

Hormones 52

Hormones Medicine Trials Production 52

Outsourcing Pharma

APRIL 24, 2024

revealed that XTANDITM (enzalutamide) has received a label extension from the European Commission, marking it as the inaugural and only novel hormone therapy endorsed for high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC) treatment in the European Union (EU).

Hormones 85

Hormones Drugs Regulation Marketing 85

Pharmaceutical Technology

JULY 13, 2022

Merck (MSD outside North America) and Orion have entered an international agreement to develop and market the latter’s investigational candidate ODM-208 to treat metastatic castration-resistant prostate cancer (mCRPC). Orion discovered and developed ODM-208 to treat hormone-dependent cancers, such as prostate cancer.

Development 264

Development Hormones Production Marketing 264

Drug Discovery World

NOVEMBER 22, 2023

The European Commission (EC) has granted marketing authorisation for YORVIPATH (palopegteriparatide) as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. YORVIPATH is Ascendis Pharma’s prodrug of parathyroid hormone (PTH 1-34), administered once daily.

Marketing 52

Marketing Drugs Hormones Medicine 52

Pharma Times

DECEMBER 8, 2021

The Evra hormonal patch can be worn discreetly and according to Gedeon Richter UK Ltd, is over 99% effective at pregnancy prevention

Hormones 110

Hormones Marketing 110

BioTech 365

AUGUST 24, 2021

Global Gynecology Drugs Market Research Report 2021-2026 – ResearchAndMarkets.com Global Gynecology Drugs Market Research Report 2021-2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global Gynecology Drugs Market, By Therapeutics (Hormonal Therapy vs. Non-Hormonal Therapy), By Indication, By Distribution Channel, (..)

Marketing 40

Marketing Hormones Research Drugs 40

XTalks

JANUARY 9, 2024

The thyroid plays a critical role in the body by producing hormones that regulate metabolism, heart rate and body temperature among others. Types of Thyroid Conditions There are several different thyroid conditions, with each affecting thyroid hormone production or the gland’s structure, leading to a range of health issues.

Hormones 105

Hormones Antibody Trials Production 105

Drug Discovery World

JUNE 1, 2023

A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2. DDW’s Megan Thomas explores three trends in the market. Varying sources suggest that China has been one to watch over recent years and continues to be going forward.

Antibody 98

Antibody Marketing Drugs Licensing 98

Fierce Pharma

SEPTEMBER 6, 2023

Royalty Pharma, a company known for ponying up chunks of cash in exchange for long-term drug royalties, has hopped on board with Ascendis Pharma's long-acting growth hormone Skytrofa. Ascendis hopes to bring its second TransCon product to the market and overcome manufacturing issues.

Manufacturing 93

Manufacturing Hormones Drugs Production 93

Delveinsight

SEPTEMBER 27, 2021

However, it has been observed that even after early therapy administration, relapse risk is substantial, and the most effective therapies pose a considerable risk with long-term administration, creating a huge unmet need for the market. The West syndrome market has different forms of ACTH available for infantile spasms.

Marketing 77

Marketing Hormones Radiology Pharma Companies 77

Pharmaceutical Technology

FEBRUARY 24, 2023

It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

STAT News

MARCH 21, 2023

A new obesity treatment being developed by Altimmune met goals for weight loss in a mid-stage clinical trial, but the data showed it doesn’t have a leg up on other popular drugs on the market.

Hormones 98

Hormones Drugs Clinical Trials Clinical Trials 98

STAT News

OCTOBER 25, 2022

The antitrust regulator in Spain has fined Merck approximately $39 million for preventing a competitor from marketing a generic version of a hormonal contraceptive, the latest effort by a European government to crack down on anti-competitive practices in the pharmaceutical industry.

Regulation 98

Regulation Hormones Manufacturing Production 98

Pharma Times

FEBRUARY 2, 2021

CHMP recommended marketing authorisation for human growth hormone therapy

Hormones 94

Hormones Marketing 94

Pharmaceutical Technology

JUNE 6, 2023

Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. Pharma Mar Overview Pharma Mar discovers, develops and markets marine-derived drugs to treat cancer. According to Globaldata, it is involved in 5 clinical trials, which are ongoing.

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

pharmaphorum

MAY 27, 2021

The two companies share marketing rights to relugolix products in North America, while Pfizer has exclusive rights elsewhere. Combining it with the hormonal drugs reduces side effects – such as bone loss – that can result from reducing oestrogen levels.

Hormones 98

Hormones Sales Marketing Drugs 98

pharmaphorum

APRIL 1, 2022

market is just beginning to heat up. And with the availability of two versions—a branded and unbranded version—the industry will watch closely how both products compete in the commercial market versus Medicare Part D plans, and whether any other insurers adopt it to their formularies. About the author.

Marketing 59

Marketing Pharmacy FDA Approval Manufacturing 59

pharmaphorum

OCTOBER 4, 2022

AstraZeneca and Merck & Co’s Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share. The post PARP rivals close in on AZ and Merck’s market leading Lynparza appeared first on.

Marketing 52

Marketing FDA Approval Hormones Drugs 52

pharmaphorum

MAY 20, 2021

NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. Hormone relapsed disease has stopped responding to hormone therapy and is usually treated with ADT alone or with Bayer’s Nubeqa (darolutamide) and ADT.

Hormones 98

Hormones Drugs Trials Manufacturing 98

pharmaphorum

SEPTEMBER 8, 2021

NICE has reversed its position on Johnson & Johnson’s oral prostate cancer therapy Erleada in patients with hormone-relapsed or hormone sensitive tumours, backing NHS use of the drug. ” The post NICE changes its mind on J&J’s Erleada in prostate cancer appeared first on.

Hormones 95

Hormones Drugs Trials Marketing 95

XTalks

JANUARY 23, 2024

Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.

Development 72

Development Hormones Drugs Trials 72

Pfizer

JANUARY 27, 2023

Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Advise patients using combined hormonal contraceptives to use an effective alternative contraceptive method or an additional barrier method of contraception.

Marketing 75

Marketing Production Drugs Licensing 75

Pharmaceutical Technology

APRIL 14, 2023

The company is expecting regulatory decisions for the drug in additional markets across the world this year. In March 2023, Eli Lilly secured expanded approval from the FDA for Verzenio (abemaciclib) to treat breast cancer patients.

Manufacturing 130

Manufacturing Drugs Hormones Packaging 130

Pharmaceutical Technology

AUGUST 8, 2022

According to the trial data, Enhertu lowered disease progression or mortality risk by 50% compared with chemotherapy according to the physician’s choice in HER2-low metastatic breast cancer patients with hormone receptor (HR)-positive disease or HR-negative disease. months compared with 5.1 months for the chemotherapy arm.

FDA Approval 264

FDA Approval HR Clinical Trials Clinical Trials 264

Pharmaceutical Technology

FEBRUARY 28, 2023

Mayne Pharma’s portfolio to be acquired comprises around 45 commercial products, four pipeline products and 40 approved, non-marketed products. It also includes several generic products focused on women’s health, a cardiovascular product, a hormonal vaginal ring, and a birth control pill.

Production 130

Production Hormones Marketing Medicine 130

pharmaphorum

FEBRUARY 18, 2022

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours.

Sales 98

Sales Drugs Hormones Pharma Production 98

Pharmaceutical Technology

MAY 25, 2023

Mellozzan contains the sleep hormone melatonin and is indicated for use in children with attention deficit hyperactivity disorder (ADHD) and sleep difficulties. The deal includes licence income for specified individual key markets along with profit sharing on future Mellozzan sales.

Hormones 130

Hormones Engineer Licensing Licensing 130

XTalks

FEBRUARY 7, 2024

Doti has worked in industry for the last 14 years, including seven years at AstraZeneca in various roles, and in small markets like Argentina as well as larger global markets. Since 2022, Dr. Doti has been focusing on the US market in hematology and oncology, working in breast, lung, GI and gynecological cancers among others.

Life Science 59

Life Science HR Hormones Marketing 59

Pharmaceutical Technology

FEBRUARY 27, 2023

The trial assessed the safety and efficacy of oral darolutamide plus ADT and chemotherapy docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC) patients. The regulatory approval is based on the data obtained from the multi-centre, double-blind, placebo-controlled, randomised Phase III ARASENS clinical trial.

Hormones 130

Hormones Trials Clinical Trials Clinical Trials 130

Pharmaceutical Technology

MAY 31, 2023

Les Laboratoires Servier overview Les Laboratoires Servier (Servier) researches, develops, manufactures, and markets drugs for treating various diseases. The company also provides generic drugs and contract development and manufacturing services across its global network.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100